ASC Therapeutics Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
ASC Therapeutics is a privately held biotechnology company focused on developing therapies intended to cure rare genetic diseases, including gene-editing and cell-based approaches. Its development pipeline is described as preclinical, with several projects targeting monogenic blood disorders that exhibit high genetic penetrance and may require immunomodulatory interventions. The company is based in Milpitas, California, and operates within the biotechnology research sector. In 2022, ASC Therapeutics announced a manufacturing partnership with Charles River Laboratories to produce ASC618, a gene therapy candidate for hemophilia A.